AbbVie's Skyrizi hangs Novartis' Cosentyx out to dry in head-to-head psoriasis study
Skyrizi, a key drug in AbbVie’s post-Humira future, has added another feather to its cap.
On Tuesday, the IL-23 inhibitor emerged superior in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
